CD274 and neoplasm: Univariate analysis showed a significantly worse survival in patients with a higher percentage (≥24.2%) of PD-L1+ monocytes in tumor tissues compared with their counterparts (median PFS: 5.7 vs. 13.5 months, P < 0.001, Figure 5C; median OS: 9.8 vs. 14.2 months, P < 0.001, Figure 5D).